<DOC>
	<DOCNO>NCT01949233</DOCNO>
	<brief_summary>The primary objective trial estimate effect allocation irbesartan , doxycycline , combination irbesartan doxycycline , compare placebo , measure elastic function aorta people Marfan syndrome enlargement aorta .</brief_summary>
	<brief_title>The Oxford Marfan Trial</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male female , age 13 year last birthday ( note upper age limit inclusion trial ) For age great equal 16 year age time enrolment , participant willing , opinion investigator , able give inform consent participation trial For aged 1315 time enrolment , participant willing , opinion investigator , able give inform assent , parent/guardian willing able give inform consent participation trial . Weight ≥ 50kg Diagnosed Marfan syndrome accord revise Ghent criterion 1996 Dilated aorta ( BSAadjusted aortic root zscore ≥2 aortic sinus Valsalva , use method Roman et al , absolute aortic root dimension &gt; 4.0cm sinus Valsalva measure use either echocardiography CMR ) If participant female childbearing potential , willing ensure effective contraception define contraception policy If participant take βblocker therapy , willing stop take one week prior CMR scan Willing , investigator 's opinion , able comply trial requirement Willing allow General Practitioner appropriate , Consultant , inform participation trial clinical finding issue may arise Female pregnant Female planning pregnancy within 6 month enrolment Female breast feed Previous aortic dissection Previous aortic surgery Bicuspid unicuspid aortic valve Scheduled elective cardiac aortic surgery within 6 month enrolment Definite diagnosis LoeysDietz ShpritzenGoldberg syndrome Known bilateral renal artery stenosis renal artery stenosis single function kidney History idiopathic intracranial hypertension Exposure angiotensin receptor antagonist , angiotensin convert enzyme inhibitor , medication contain compound 3 month prior enrolment trial Absolute indication angiotensin receptor antagonist , angiotensin convert enzyme inhibitor , doxycycline antibiotic tetracycline class enrolment Taking βblocker therapy indication Marfan syndrome Participant participate another research study involve investigational medicinal product device 3 month prior enrolment Renal impairment moderate severe degree ( eGFR &lt; 60 mls/min/1.73m2 ) Hyperkalaemia ( &gt; 5.1 mmol/L ) Significant hepatic impairment ( ALT AST &gt; 3 time upper limit normal ) History allergic reaction clinically significant intolerance irbesartan constituent ; angiotensin receptor blocker / antagonist ; angiotensin convert enzyme inhibitor , doxycycline constituent , placebo medication constituent Contraindications MRI ( e.g . implantable cardiac electronic device , claustrophobia , intracranial aneurysm clip metallic ocular foreign body etc . ) Participant currently require take likely required start , 6 month follow enrolment , medicinal product know suspected interact , clinically significant extent , irbesartan include : potassium supplementation , potassium spar diuretic , lithium , regular use antacid contain aluminium magnesium hydroxide Participant currently require take likely required start , 6 month follow enrolment , medicinal product know suspected interact , clinically significant extent , doxycycline include ergotamine methysergide . This include drug know induce cytochrome P450 system clinically significant extent , include limited , carbamazepine , phenytoin , rifampicin , griseofulvin , barbiturates sulphonylureas . Alcohol dependence Any significant disease , disorder circumstance ( e.g . terminal illness ) , , opinion Investigator , may either put participant risk trial , may introduce significant bias trial , may affect participant 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>